GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neuren Pharmaceuticals Ltd (OTCPK:NURPF) » Definitions » Valuation Rank

NURPF (Neuren Pharmaceuticals) Valuation Rank


View and export this data going back to 2005. Start your Free Trial

What is Neuren Pharmaceuticals Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Neuren Pharmaceuticals Valuation Rank Related Terms

Thank you for viewing the detailed overview of Neuren Pharmaceuticals's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Neuren Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neuren Pharmaceuticals Ltd (OTCPK:NURPF) » Definitions » Valuation Rank
Comparable Companies
ASX:BOT ASX:OPT ASX:CU6 ASX:PYC ASX:MSB ASX:CUV ASX:IMM ASX:OCC ASX:IMU ASX:DXB VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
NK9:Germany NEU:Australia
Address
697 Burke Road, Suite 201, Camberwell, Melbourne, VIC, AUS, 3124
Website
https://www.neurenpharma.com
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. The Group has two reportable operating segments, Commercial Products and Research and Development. It derives maximum revenue from Commercial Products.